Engineering of Stable Cell Lines Expressing TRPV Cation Channel Proteins

表达 TRPV 阳离子通道蛋白的稳定细胞系的工程改造

• 批准号: 521672-2017
• 负责人: Weaver, Ian
• 金额: $ 1.81万
• 依托单位: Dalhousie University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=639334
• 关键词: Engineering; Stable; Cell; Lines; Expressing

Soricimed Biopharma, Inc. is a Sackville/Moncton, New Brunswick based company developingbiopharmaceutical compounds based on soricidin, a paralytic protein found in the saliva of the NorthernShort-tailed Shrew. SOR-C13, the company's lead compound, is a synthetic, 13-mer peptide whose therapeuticactivity is based on its interaction with a calcium channel, TRPV6, whose expression is elevated in certain celltypes (e.g. cancer cells). Also, derivatives of SOR-C13 (C-peptides) can be used as vehicles to deliver otherdrugs directly into TRPV6-bearing cells. Optimization of this drug delivery platform is hampered by thecurrent lack of a significant in-house tool; a stable cell line overexpressing the TRPV6 channel. Under thisEngage Grant, Dr. Weaver's lab will develop this cell line, allowing Soricimed to determine what properties ofthe C-peptide derivatives improve their interaction with TRPV channels and hence their ability to target andenter cells bearing these channels. This gained knowledge would in turn lead to expansion of the company'sproduct line with new and improved therapeutic C-peptides, and novel C-peptide/drug conjugates targetingspecific cell types. Broadening and solidifying the company's pipeline with such products will lead topartnerships with larger biopharma companies and expand Soricimed's drug marketability.

Soricimed Biopharma, Inc. 是一家总部位于新不伦瑞克省萨克维尔/蒙克顿的公司，开发基于 soricidin 的生物制药化合物，soricidin 是一种在北短尾鼩鼱唾液中发现的麻痹蛋白。该公司的先导化合物 SOR-C13 是一种合成的 13 聚体肽，其治疗活性基于其与钙通道 TRPV6 的相互作用，TRPV6 的表达在某些细胞类型（例如癌细胞）中升高。此外，SOR-C13（C 肽）的衍生物可用作载体，将其他药物直接输送到携带 TRPV6 的细胞中。由于目前缺乏重要的内部工具，该药物输送平台的优化受到阻碍；过度表达 TRPV6 通道的稳定细胞系。根据这项参与资助，Weaver 博士的实验室将开发这种细胞系，使 Soricimed 能够确定 C 肽衍生物的哪些特性可以改善它们与 TRPV 通道的相互作用，从而提高它们靶向并进入带有这些通道的细胞的能力。所获得的知识反过来将导致公司产品线的扩展，包括新的和改进的治疗性 C 肽，以及针对特定细胞类型的新型 C 肽/药物缀合物。通过此类产品拓宽和巩固公司的产品线将导致与更大的生物制药公司建立合作伙伴关系，并扩大 Soricimed 的药物市场。